Revvity Shares Climb on Strong Q4 Revenue, Raised Full-Year Outlook
The life sciences company announced preliminary fourth-quarter revenue of approximately $772 million and expects 2025 earnings to exceed its previous guidance.
Shares of Revvity, Inc. (NYSE: RVTY) gained traction on Monday after the company released strong preliminary financial results for the fourth quarter of 2025 and raised its full-year earnings forecast, signaling underlying strength in its life sciences and diagnostics businesses.
The Waltham, Massachusetts-based company announced it anticipates fourth-quarter revenue of approximately $772 million. This figure represents a reported growth of around 6% and organic growth of 4% from the prior-year period, surpassing Wall Street expectations. The positive top-line results prompted a bullish revision to its profit outlook.
Revvity stated that it now expects its full-year 2025 adjusted earnings per share (EPS) to come in above the high end of its previously issued guidance of $4.90 to $5.00. The company's total revenue for the full 2025 fiscal year is projected to be approximately $2.855 billion, according to the preliminary announcement.
The updated guidance suggests growing confidence from management in the face of a complex macroeconomic environment. Revvity, with a market capitalization of approximately $12.1 billion, is a key player in the diagnostics and life sciences sectors, providing instruments, reagents, and software solutions to a range of scientific and clinical markets. The strong performance hinted at in the preliminary release is causing some investors to re-evaluate growth prospects in the broader diagnostics and research space as noted by market analysts.
Prior to the announcement, analysts had a consensus 12-month price target of $114.62 on the stock. The company's stock has traded in a range between $81.30 and $128.00 over the past 52 weeks, and the latest news could provide a catalyst for a move toward the upper end of that range.
The preliminary results did not include a detailed breakdown of performance between Revvity's two primary segments: Life Sciences and Diagnostics. Investors will be keenly awaiting the full, audited results for insight into which areas are driving the growth. The company has scheduled a conference call and webcast to discuss its complete fourth-quarter and full-year 2025 financial results on Monday, February 2, 2026, before the market opens.
This early announcement provides a positive data point for the health-care tools sector, which has been navigating a post-pandemic normalization in demand. Revvity's ability to drive organic growth and raise its earnings forecast points to robust demand for its products and effective operational management.